Bioprojet
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
6
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 26, 2027The maintenance fee for (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications (US 9,242,959) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
- 1 fee due Aug 9, 2027The maintenance fee for 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands (US 9,255,101) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,802,678 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 8,017,646 | Histamine H3-receptor ligands and their therapeutic application In force · From the USPTO record | In force | From the USPTO record | |
| US 8,318,203 | Form of administration of racecadotril In force · From the USPTO record | In force | From the USPTO record | |
| US 8,106,041 | Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs In force · From the USPTO record | In force | From the USPTO record | |
| US 8,486,947 | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 8,207,197 | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine In force · From the USPTO record | In force | From the USPTO record | |
| US 8,802,664 | Benzazole derivatives as histamine H4 receptor ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 9,029,357 | Benzazole Derivatives as Histamine H4 Receptor Ligands In force · Medium confidence | In force | Medium confidence | |
| US 9,439,853 | Form of administration of enkephalinase inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,242,959 | (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 17: 1 patent in force now held by others · 8 lapsed for an unpaid fee · 29 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 5 no status recorded